Difference between revisions of "Team:Toulouse France/Description"

 
(25 intermediate revisions by 3 users not shown)
Line 3: Line 3:
  
 
<html>
 
<html>
 +
 +
<style>
 +
.texteb {
 +
    color: #191919;
 +
    font-family: 'Open Sans';
 +
    font-size: 15px;
 +
    margin: 20px 10px;
 +
    line-height: 24px;
 +
    text-align: justify;
 +
}
 +
 +
.title1 {
 +
    color: #870721;
 +
    font-family: 'Open Sans';
 +
    font-weight: 600;
 +
    font-size: 30px;
 +
    margin: 0 0 33px 0;
 +
    border: none;
 +
text-align:center;
 +
}
 +
 +
</style>
  
 
 
Line 13: Line 35:
 
 
 
<div id="pageintro" class="hoc clear" style="padding:300px 0px;">  
 
<div id="pageintro" class="hoc clear" style="padding:300px 0px;">  
<p class="sec_title" style="background-color:rgba(1,1,1,0.5);">Project</p>
+
<p class="sec_title" style="background-color:rgba(1,1,1,0.5);">Backbones description</p>
 
 
 
</div>
 
</div>
Line 21: Line 43:
 
<!-- ################################################################################################ -->
 
<!-- ################################################################################################ -->
  
<div class="column full_size" style="margin-top:30px; margin-left: 10%; margin-right: 10%;">
 
  
<div style="clear: both;"></div>
+
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.8.3/jquery.min.js"></script>
+
<div class="column full_size" style="text-align:justify; font-size:14px; color:black;">
+
<div style="padding-top:30px; padding-left: 10%; padding-right: 10%;">
<div class="Ppanel">
+
<div class="hoc container clear">
+
<div class="subpanel1">
+
 +
<u><p class="title1" id="select1">Backbone</p></u>
 +
<p class="texteb">  
 
 
<div style="position:relative;bottom:0px">
+
The use of replicative plasmid in <i>Bacillus subtilis</i> is not as usual as in <i>E. coli</i>.
<div class="cont">
+
Only one of such plasmid is described in the iGEM registry (<a href="http://parts.igem.org/Part:BBa_K823026">pSB<sub>BS</sub>0K-P</a> from iGEM Munich 2012;
<p style="font-size:20px;line-height:26px; text-align:center;"><b>How to help Lascaux ?</b></p>
+
<a href="http://parts.igem.org/Part:BBa_K823026">BBa_K823026</a> and its slightly modified form <a href="http://parts.igem.org/Part:BBa_K1351040">BBa_K1351040</a>).
<hr style="width:100%; margin:10px 0px; color:black; background-color:black; height:1px;" />
+
Since none of them were available from the registry, we eventually got <a href="http://parts.igem.org/Part:BBa_K1351040">BBa_K1351040</a> from ex-Munich iGEMers (thanks guys!).
</div>
+
However, this plasmid is already huge (9358 bp), and we needed to insert great fragments inside.
 +
Our first attempts to clone in <a href="http://parts.igem.org/Part:BBa_K1351040">BBa_K1351040</a> failed. We therefore decided to operate a reduction of the plasmid size.
 +
<br><br>
 +
 +
</p>
 +
 +
 +
 +
<u><p class="title1" id="select1">pSB<sub>BS</sub>0K-Mini: new part <a href="http://parts.igem.org/Part:BBa_K1937001">BBa_K1937001</a></p></u>
 +
<p class="texteb">
 +
We reasoned that most of the pSB<sub>BS</sub>0K-P plasmid content were of no need to our project (<i>lacY, rfp,
  
<div id="psdesc" class="spdesc">
+
lacI</i>…). Since supressing these elements also suppressed the suffix and prefix, primers with new suffix
<div class="cont">
+
<p style="font-size:14px;">
+
<b>Introduction</b>
+
<br><br>Just like in many countries, prehistorical men walked into our lands.  
+
However, they left a trace of their passage in France: the Lascaux cave, which is one of the most important heritages we have.
+
What is so specific about this cave ?
+
<br>it is not just a simple cave, cold, rocky and moist. The Lascaux cave is so much more.
+
<br>Decorated with organic and minerals pigments, it is home to parietal paintings and many frescoes and engravings cover the walls.
+
<br>Bulls, aurochs and horses are part of these representations, and testify the way of life of our ancestors.
+
  
</p>
+
and prefix were designed to amplify the needed regions (selection markers and replication origins;
</div>
+
</div>
+
+
<div id="dsdesc" class="spdesc">
+
<div class="cont">
+
<p style="font-size:14px;">
+
<b>Background - the historic of the cave</b>
+
<br>
+
<br>
+
As soon as the cave was discovered in 1940, people came from the whole country and abroad to visit it. However, the carbon dioxide and the water vapour released by their breath started to disrupt the cave’s ecosystem. The damages caused by these air changements are at the origin of the first crisis that the Lascaux cave knew. Two kinds of contaminations were observed: the limestone formation on the walls, which was called the white disease, and the green algae growth, named the green disease.
+
Then, white mold and black stains appeared on the walls and the floor, and were characteristical of the second and the third crisis respectively. These contaminations flow from fungi and bacteria proliferation.
+
+
</p>
+
+
</div>  
+
</div>
+
  
<div id="thdesc" class="spdesc">
+
figure 1). <i>Nhe1</i> restriction site was also added at the 5’ end of each primers to circularize the PCR
<div class="cont">
+
<p style="font-size:14px;">
+
<b>Treatment of the cave</b>
+
<br>
+
<br>
+
Curing the cave was a priority. Consequently, treatments like biocid or antibiotics were tried.
+
The success of these initiatives worked temporarily, but new microorganisms developed on the organic wastes.
+
According to the last reviews about the Lascaux cave, bacteria (Bacillus subtilis, Pseudomonas species, Rhizobium radiobacter,...) and fungi (Fusarium sp., Ochroconis anomalaand,  Aspergillus sp., Acremonium sp.,...) are currently in the cave.
+
Nowadays, even if the cave situation is steady, microorganisms covering frescoes are still present.
+
  
</p>
+
product.
</div>
+
 
</div>
+
<!-- ######  FIGURE  ##### -->
 +
<center><img src="https://static.igem.org/mediawiki/2016/e/e7/Toulouse_France_backbone1.jpg" style="width:60%; margin:20px 20px;"></center>
 +
<b style="font-size:12px;">
 +
Figure 1: reduction of the pSB<sub>BS</sub>0K-P plasmid. Position of the primers are indicated by the blue arrow on pSB<sub>BS</sub>0K-P (left part of the figure). The resulting PCR fragment is the blue pointed line. After digestion by NheI and self-ligation, the resulting pSB<sub>BS</sub>0K-Mini plasmid was obtained (right part of the figure).
 +
</b>
 +
<br><br>
 +
 
 
<div id="tcdesc" class="spdesc">
+
The new plasmid size is smaller by 3604 bp. It was purified from <i>E. coli</i> and used to
<div class="cont">
+
<p style="font-size:14px;">
+
<b>Why did we choose this subject?</b>
+
<br>
+
<br>
+
At the beginning of the iGEM adventure, almost twenty subjects were considered.  
+
Every thematic was intertwined with the other, like environment, health, and mostly art.
+
After months of intense brainstorming, we finally decided to work on the conservation of the Lascaux cave.
+
We wanted to choose a project that was personal and original.
+
The Lascaux cave then imposed itself.
+
It is part of the French heritage, and was added to the UNESCO World Heritage Sites list.
+
It has been threatened of destruction since decades now, and organizations from all around the world have gathered to solve the Lascaux cave crisis.
+
<br>The Lascaux cave is what traces us back to our humanity.  
+
<br>The first men lived there and some of the first pieces of art ever were created there.
+
  
</p>
+
successfully transform <i>B. subtilis</i>. Integrity of the whole sequence was assessed by
</div>
+
</div>
+
</div>
+
</div>
+
+
<a href="">
+
<div id="pspanel" class="subpanel2"  onmouseover="chgtrans(this)">
+
<img src="https://static.igem.org/mediawiki/2016/6/66/Toulouse_France_p3.jpg"  width="150px" height="600px"/>
+
<div class="titlebox">
+
<div style="width:60%;margin-left:20%;margin-bottom:20px; font-size:12px; background-color:rgba(255,255,255,0.3));"><hr></div>
+
<p style=" background-color:rgba(255,255,255,0.2); margin: 2px 3px; text-align:center; font-size:18px;">
+
Introduction
+
</p>
+
</div>
+
</div>
+
</a>
+
+
<a href="">
+
<div id="dspanel" class="subpanel2"  onmouseover="chgtrans(this)">
+
<img src="https://static.igem.org/mediawiki/2016/6/66/Toulouse_France_p3.jpg"  width="150px" height="600px"/>
+
<div class="titlebox">
+
<div style="width:60%;margin-left:20%;margin-bottom:20px; font-size:12px; background-color:rgba(255,255,255,0.3));"><hr></div>
+
<p style=" background-color:rgba(255,255,255,0.2); margin: 2px 3px; text-align:center; font-size:18px;">
+
The historic of the cave
+
</p>
+
</div>
+
</div>
+
</a>
+
  
<a href="">
+
sequencing using 10 primers distributed all along the sequence. This new plasmid was
<div id="thpanel" class="subpanel2"  onmouseover="chgtrans(this)">
+
<img src="https://static.igem.org/mediawiki/2016/6/66/Toulouse_France_p3.jpg"  width="150px" height="600px"/>
+
<div class="titlebox">
+
<div style="width:60%;margin-left:20%;margin-bottom:20px; font-size:11px; background-color:rgba(255,255,255,0.3));"><hr></div>
+
<p style=" background-color:rgba(255,255,255,0.2); margin: 2px 3px; text-align:center; font-size:18px;">
+
Treatment of the cave
+
</p>
+
</div>
+
</div>
+
</a>
+
  
<a href="">
+
then used to create most of the <i>Bacillus subtilis</i> parts of our project, demonstrating its
<div id="tcpanel" class="subpanel2"  onmouseover="chgtrans(this)">
+
<img src="https://static.igem.org/mediawiki/2016/6/66/Toulouse_France_p3.jpg"  width="150px" height="600px"/>
+
<div class="titlebox">
+
<div style="width:60%;margin-left:20%;margin-bottom:20px; font-size:12px;"><hr></div>
+
<p style=" background-color:rgba(255,255,255,0.2); margin: 2px 3px; text-align:center; font-size:18px;">
+
Why did we choose this subject?
+
</p>
+
</div>
+
</div>
+
</a>
+
  
</div>
+
efficiency as a new backbone for <i>Bacillus</i> based projects.
 
+
</div>
+
</p>
 +
 +
<u><p class="title1" id="select1">OriKan (new part <a href="http://parts.igem.org/Part:BBa_K1937002">BBa_K1937002</a>): and they all became <i>Bacillus</i> plasmids…</p></u>
 +
<p class="texteb">
 
 
+
With the success of the pSB<sub>BS</sub>0K-Mini, we decided that we should try to go even further by isolating
<div class="column full_size">
+
<div class="hoc container clear">
+
+
<p align="justify" style="font-size:14px; padding: 15px 50px;">
+
+
  
 +
what is the very essence of this replicative <i>Bacillus</i> plasmid: its <i>Bacillus repU</i> origin and its kanamycin
  
<b style="font-size:16px;">Containment: </b>
+
resistance gene. We amplified the region containing these two elements with primers carrying the
  
 +
iGEM suffix and prefix (figure 2).
  
 +
<!-- ######  FIGURE  ##### -->
 +
<center><img src="https://static.igem.org/mediawiki/2016/c/ca/Toulouse_France_backbone2.jpg" style="width:60%; margin:20px 20px;"></center>
 +
<b style="font-size:12px;">
 +
Figure 2: creation of the OriKan cassette. Position of the primers are indicated by the blue arrow on pSB<sub>BS</sub>0K-P (left part of the figure). The resulting PCR fragment is the blue pointed line. After digestion by <i>EcoRI</i> and <i>PstI</i> and ligation in the pSB1C3 plasmid, the resulting pSB1C3-OriKan plasmid was obtained (right part of the figure).
 +
</b>
 +
<br><br>
 +
The fragment was then sub-cloned in the pSB1C3 plasmid (between the <i>EcoRI/PstI</i> restriction sites).
  
<br><br>Ours project involved release of genetically modified bacteria in the cave. Lascaux cave is not a completely closed system; there is interaction with external environment due to water infiltration. The threat of releasing bacteria in the cave is the possibility of horizontal gene transfer to native bacteria. The horizontal gene transfer (or lateral gene transfer) is transmission of DNA and it is known to occur between different species. Here the aim of the containment module was to provide transfer of non natural genetic content to endogenous cave bacteria
+
We checked the capacity of this new pSB1C3-Orikan plasmid to maintain in <i>Bacillus subtilis</i> and we
<br><br>Paleotilis project involve more than 15 kb of gene therefore a two plasmid construction was necessary. To provide any of these plasmids dissemination a double toxin-antitoxin was designed (Figure1). One plasmid contains antitoxin 1 and toxin 2, the other contains antitoxin 2 and toxin 1. This construction divide toxin-antitoxin couples, the toxin is on a different plasmid then it corresponding antitoxin. Through this system both plasmids are compulsory for bacteria survival. If endogenous bacteria of the cave received a single plasmid, toxin expression will lead to death. In the same time this design obligates the cell to maintain both (or none) plasmids.
+
<br><br>The toxin –antitoxin are under the control of a constitutive promoter of Bacillus subtilis: Pveg (BBa_K143012), to assure a constant expression of the toxin (Figure2). The two pairs of Toxin-Antitoxin combinations selected for this project are MazF/MazE and Zeta/Epsilon. Both are type II Toxin-Antitoxin systems, meaning that antitoxin and toxin are proteins and the protein toxin is inhibited by the binding of a protein antitoxin (Wang et al., 2013)
+
  
 +
were delighted to obtain clones. The actual presence of pSB1C3-Orikan in this colonies was assessed
  
 +
by PCR (figure 3). The sequence integrity of the OriKan cassette was also verified.
  
 +
<!-- ######  FIGURE  ##### -->
 +
<center><img src="https://static.igem.org/mediawiki/2016/1/18/Toulouse_France_backbone3.jpg" style="width:30%; margin:20px 20px;"></center>
 +
<b style="font-size:12px;">
 +
Figure 3: validation of the pSB1C3-Orikan presence in <i>B. subtilis</i>. PCR on colonies was performed using primers hybridizing in the kanamycine resistance gene and in the suffix. The colonies were issued from the transformation of <i>B. subtilis</i> by pSB1C3-Orikan (assays), by the  pSB<sub>BS</sub>0K-P plasmid (negative control), or from the transformation of <i>E. coli</i> by pSB1C3-Orikan (positive control).
 +
</b>
 +
 +
<br><br>
 +
These results demonstrate that the OriKan biobrick is sufficient to turn any pSB1C3 plasmid into a
  
 +
<i>Bacillus subtilis</i> compatible replicative plasmid.
 +
<br><br>
 +
</p>
  
<br><br>Figure 1: Design of the containment system of paleotilis
+
<u><p class="title1" id="select1">Conclusions and perspectives</p></u>
 +
<p class="texteb">
  
 +
The start of our project has been complicated by the absence of available replicative plasmid for
  
<br><br><b style="font-size:16px;">MazF /MazE toxin-antitoxin couple</b>
+
<i>Bacillus subtilis</i> in the registry. Even managing to obtained one was not the end of our quest since it
  
<br><br>The mazEF operon was the first Toxin-Antitoxin system found on the Escherichia coli chromosome. It is related to the kis/kid module on plasmid R1 (Bravo et al., 1987). MazF is an endoribonuclease which specifically cleaves mRNAs at ACA sequences (Zhang et al., 2005). In Escherichia coli mazF inhibits protein synthesis by cleaving mRNAs. The excess of MazF toxin (in case of single plasmid) provide by our system will lead to bactericidal effect.
+
appears to be too big for further sub-cloning purposes. In this context, obtaining the pSB<sub>BS</sub>0K-Mini
  
<br><br><b style="font-size:16px;">Epsilon/Zeta toxin-antitoxin couple</b>
+
has been a great step forward for us as it allowed a fast progression of our project cloning steps.
  
<br><br>The Epsilon and Zeta Toxin-antitoxin system was discovered in Streptococcus pyogenes more precisely in the low-copy-number plasmid pSM19035, its function is to stabilize plasmid segregation. The zeta toxin has shown toxic effects on Escherichia coli, Bacillus subtilis and Saccharomyces cerevisiae (Zielenkiewicz and Cegłowski, 2005). The zeta toxins phosphorylate the peptidoglycane precursor that inhibits the bacterial peptidoglycane synthesis (Mutschler et al., 2011). Without abilities to cell wall synthesis bacteria are lyses.  
+
<br><br>Moreover, we are also very proud of the OriKan biobrick. There was no such part in the registry. Its
  
<br><br><b style="font-size:16px;">Cloning approach:</b>
+
capacity to simply functionalize any registry part for <i>Bacillus subtilis</i> (and likely some other gram
  
<br><br>We synthesized our constructions thanks to IDT gblock. Each fragment contains a toxin but not its corresponding antitoxin. Therefore building our plasmids needed a strategy to avoid cell death. We chose to use theophylline sensitive riboswitch. In the absence of the ligand RBS sequence is available and RNA translation is possible. In ligand presence RNA shape change and RBS is not accessible (Topp and Gallivan, 2008). In this case theophylline riboswitch is among our toxin sequence. Theophylline presence represses the toxin expression. These conditions allow us to transform our bacteria with a single plasmid in a media containing 1mM Theophylline.
+
positive strains) is invaluable for the ever growing numbers of iGEM projects based on these
  
 
+
organisms. We therefore applied for the OriKan biobrick to be selected as “best composite part”.
<br><br><b style="font-size:16px;">References </b>
+
 
+
<br><br>Bravo, A., de Torrontegui, G., and Díaz, R. (1987). Identification of components of a new stability system of plasmid R1, ParD, that is close to the origin of replication of this plasmid. Mol. Gen. Genet. MGG 210, 101–110.
+
<br>Mutschler, H., Gebhardt, M., Shoeman, R.L., and Meinhart, A. (2011). A novel mechanism of programmed cell death in bacteria by toxin-antitoxin systems corrupts peptidoglycan synthesis. PLoS Biol. 9, e1001033.
+
<br>Topp, S., and Gallivan, J.P. (2008). Riboswitches in unexpected places—A synthetic riboswitch in a protein coding region. RNA 14, 2498–2503.
+
<br>Wang, X., Lord, D.M., Hong, S.H., Peti, W., Benedik, M.J., Page, R., and Wood, T.K. (2013). Type II Toxin/Antitoxin MqsR/MqsA Controls Type V Toxin/Antitoxin GhoT/GhoS. Environ. Microbiol. 15, 1734–1744.
+
<br>Zhang, Y., Zhang, J., Hara, H., Kato, I., and Inouye, M. (2005). Insights into the mRNA Cleavage Mechanism by MazF, an mRNA Interferase. J. Biol. Chem. 280, 3143–3150.
+
<br>Zielenkiewicz, U., and Cegłowski, P. (2005). The Toxin-Antitoxin System of the Streptococcal Plasmid pSM19035. J. Bacteriol. 187, 6094–6105.
+
<br><br>
+
http://parts.igem.org/Part:BBa_K1493602
+
<br>http://parts.igem.org/Part:BBa_K1096001
+
+
 
</p>
 
</p>
 
 
<a href="https://2016.igem.org/Team:Toulouse_France/Demonstrate" title="Results">
 
<div class="subpanel3" >
 
Results
 
</div>
 
</a>
 
 
</div>
 
</div>
 
</div>
 
</div>
 +
</div>
 +
 +
<div class="column full_size">
  
  
 +
<center>
 +
<a class="button-home" href="https://2016.igem.org/Team:Toulouse_France/Design" style="border: 1px solid #282828;-webkit-border-radius: 5px;-moz-border-radius: 5px;border-radius: 5px;
 +
padding: 15px 15px; color: black; text-decoration: none; font-size: 18px; background: none; display: block; width: 250px; background-color:#7FFFD4">BACK: Design of our project</a>
 +
 +
<br><br>
 +
<a class="button-home" href="https://2016.igem.org/Team:Toulouse_France/Experiments" style="border: 1px solid #282828;-webkit-border-radius: 5px;-moz-border-radius: 5px;border-radius: 5px;
 +
padding: 15px 15px; color: black; text-decoration: none; font-size: 18px; background: none; display: block; width: 250px; background-color:#F4A460">NEXT: Our results</a>
 +
</center>
 +
 +
</div>
 +
 +
 
<script type="text/javascript" src="https://2016.igem.org/Template:Toulouse_France/MAINJS"></script>
 
<script type="text/javascript" src="https://2016.igem.org/Template:Toulouse_France/MAINJS"></script>
  
 
 
 
</div>
 
 
 
 
</html>
 
</html>
  
 +
{{Toulouse_France/Sponsors}}
 
{{Toulouse_France/Footer}}
 
{{Toulouse_France/Footer}}

Latest revision as of 23:13, 19 October 2016

iGEM Toulouse 2016

Backbones description

Backbone

The use of replicative plasmid in Bacillus subtilis is not as usual as in E. coli. Only one of such plasmid is described in the iGEM registry (pSBBS0K-P from iGEM Munich 2012; BBa_K823026 and its slightly modified form BBa_K1351040). Since none of them were available from the registry, we eventually got BBa_K1351040 from ex-Munich iGEMers (thanks guys!). However, this plasmid is already huge (9358 bp), and we needed to insert great fragments inside. Our first attempts to clone in BBa_K1351040 failed. We therefore decided to operate a reduction of the plasmid size.

pSBBS0K-Mini: new part BBa_K1937001

We reasoned that most of the pSBBS0K-P plasmid content were of no need to our project (lacY, rfp, lacI…). Since supressing these elements also suppressed the suffix and prefix, primers with new suffix and prefix were designed to amplify the needed regions (selection markers and replication origins; figure 1). Nhe1 restriction site was also added at the 5’ end of each primers to circularize the PCR product.

Figure 1: reduction of the pSBBS0K-P plasmid. Position of the primers are indicated by the blue arrow on pSBBS0K-P (left part of the figure). The resulting PCR fragment is the blue pointed line. After digestion by NheI and self-ligation, the resulting pSBBS0K-Mini plasmid was obtained (right part of the figure).

The new plasmid size is smaller by 3604 bp. It was purified from E. coli and used to successfully transform B. subtilis. Integrity of the whole sequence was assessed by sequencing using 10 primers distributed all along the sequence. This new plasmid was then used to create most of the Bacillus subtilis parts of our project, demonstrating its efficiency as a new backbone for Bacillus based projects.

OriKan (new part BBa_K1937002): and they all became Bacillus plasmids…

With the success of the pSBBS0K-Mini, we decided that we should try to go even further by isolating what is the very essence of this replicative Bacillus plasmid: its Bacillus repU origin and its kanamycin resistance gene. We amplified the region containing these two elements with primers carrying the iGEM suffix and prefix (figure 2).

Figure 2: creation of the OriKan cassette. Position of the primers are indicated by the blue arrow on pSBBS0K-P (left part of the figure). The resulting PCR fragment is the blue pointed line. After digestion by EcoRI and PstI and ligation in the pSB1C3 plasmid, the resulting pSB1C3-OriKan plasmid was obtained (right part of the figure).

The fragment was then sub-cloned in the pSB1C3 plasmid (between the EcoRI/PstI restriction sites). We checked the capacity of this new pSB1C3-Orikan plasmid to maintain in Bacillus subtilis and we were delighted to obtain clones. The actual presence of pSB1C3-Orikan in this colonies was assessed by PCR (figure 3). The sequence integrity of the OriKan cassette was also verified.
Figure 3: validation of the pSB1C3-Orikan presence in B. subtilis. PCR on colonies was performed using primers hybridizing in the kanamycine resistance gene and in the suffix. The colonies were issued from the transformation of B. subtilis by pSB1C3-Orikan (assays), by the pSBBS0K-P plasmid (negative control), or from the transformation of E. coli by pSB1C3-Orikan (positive control).

These results demonstrate that the OriKan biobrick is sufficient to turn any pSB1C3 plasmid into a Bacillus subtilis compatible replicative plasmid.

Conclusions and perspectives

The start of our project has been complicated by the absence of available replicative plasmid for Bacillus subtilis in the registry. Even managing to obtained one was not the end of our quest since it appears to be too big for further sub-cloning purposes. In this context, obtaining the pSBBS0K-Mini has been a great step forward for us as it allowed a fast progression of our project cloning steps.

Moreover, we are also very proud of the OriKan biobrick. There was no such part in the registry. Its capacity to simply functionalize any registry part for Bacillus subtilis (and likely some other gram positive strains) is invaluable for the ever growing numbers of iGEM projects based on these organisms. We therefore applied for the OriKan biobrick to be selected as “best composite part”.



Contacts